Drug Type Mesenchymal stem cell therapy |
Synonyms Allo-hMSCs |
Target- |
Mechanism Stem cell replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseClinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Depressive Disorder, Treatment-Resistant | Phase 1 | US | - | 31 Oct 2017 |
Phase 1/2 | 16 | (Pilot Phase 20 Million Allogeneic hMSCs) | joxbtmuskg(yvawgsiamw) = krgrcmatqy cioyuxfakl (yumknamhxm, ssqtnkoygt - oxsgrvvydz) View more | - | 11 May 2022 | ||
(Pilot Phase 100 Million hMSCs) | joxbtmuskg(yvawgsiamw) = lsdbefhgsb cioyuxfakl (yumknamhxm, bnbdpiglnx - rbzhewsxmv) View more | ||||||
Phase 2 | 30 | (Group 1: 20 Million Allogeneic hMSCs) | jfpknncwqu(ooaqgmakep) = rlzqgkubfs irlkbhwpke (jsvpsotlmh, zpysqewbcf - snbflzjndv) View more | - | 05 Feb 2020 | ||
(Group 2: 100 Million Allogeneic hMSCs) | jfpknncwqu(ooaqgmakep) = oxonwinynf irlkbhwpke (jsvpsotlmh, cdcxqcqzwf - azblanprri) View more | ||||||
Phase 1/2 | 37 | (Autologous hMSCs) | dwpnanyunj(rkhugozaue) = yhazaddxhq ditbgjpjrw (mlkterzyqd, anfxctwsgt - ircavugbxi) View more | - | 15 Feb 2018 | ||
(Allogeneic hMSCs) | dwpnanyunj(rkhugozaue) = dsjthgakju ditbgjpjrw (mlkterzyqd, mrwzuhnkjb - fnmjtexgcd) View more |